Methodological approaches to evaluate the impact of FDA drug safety communications

Aaron S. Kesselheim, Eric G. Campbell, Sebastian Schneeweiss, Paula Rausch, Brian M. Lappin, Esther H. Zhou, John D. Seeger, John S. Brownstein, Steven Woloshin, Lisa M. Schwartz, Timothy Toomey, Gerald J. Dal Pan, Jerry Avorn